Valeriana species and insomnia: multi-organ mechanisms and translational perspectives.
Clinical Snapshot
PICO Framework
| P — Population | Patients with insomnia or sleep disorders |
| I — Intervention | Valeriana species (V. officinalis L. and V. jatamansi Jones) preparations |
| C — Comparator | Conventional treatments (cognitive behavioral therapy, pharmacological agents) or placebo |
| O — Outcomes | Sleep quality, sedative effects, neurotransmitter modulation, oxidative stress markers, safety profiles |
Bottom Line
This systematic review examines Valeriana species for insomnia treatment but suffers from significant methodological limitations. While preclinical evidence supports sedative and neuroprotective mechanisms through neurotransmitter modulation and oxidative stress reduction, clinical evidence remains inconsistent. The authors acknowledge substantial variability in formulations, dosages, and individual responses. Without formal quality assessment, quantitative synthesis, or GRADE evaluation, the evidence base remains insufficient to support routine clinical use. The favorable safety profile is encouraging, but standardized preparations and rigorous randomized controlled trials are needed before evidence-based recommendations can be made. Australian clinicians should await higher-quality evidence before incorporating Valeriana into standard insomnia management protocols.
Key Findings
P Value: Not applicable - narrative review
Effect Size: Not quantified - qualitative synthesis only
Primary Outcome: Valeriana species demonstrate sedative and neuroprotective effects through neurotransmitter modulation
Nnt Or Sensitivity: Not calculated due to lack of quantitative synthesis
Confidence Interval: Not reported
Clinical Application
Moderate - requires standardized formulations and dosing protocols Relevant as complementary medicine; TGA regulation of herbal preparations applies; may complement RACGP sleep disorder guidelines as adjunctive therapy Adults with insomnia seeking complementary therapeutic options
Abstract
CONTEXT: Insomnia is a common sleep disorder that substantially impairs quality of life. Conventional treatments, including cognitive behavioral therapy and pharmacological agents, are often limited by side effects and insufficient long-term safety data. Valeriana species, such as Valeriana officinalis L. and Valeriana jatamansi Jones, have been traditionally used for their sedative and neuroprotective properties. OBJECTIVE: This review evaluates the therapeutic potential of Valeriana species for insomnia, emphasizing their pharmacological mechanisms, multi-organ effects, and evidence from preclinical and clinical studies. METHODS: A systematic literature search was performed in databases including PubMed and Web of Science. Studies addressing Valeriana-induced sleep regulation, neurotransmitter modulation, oxidative stress reduction, and neural, hepatic, and gastrointestinal interactions were included to assess efficacy and safety. RESULTS: Valeriana species modulate neurotransmission, mitigate oxidative stress, and influence hepatic and gastrointestinal functions. Preclinical studies support their sedative and neuroprotective effects, while clinical outcomes vary with formulation, dosage, and individual response. Overall, safety profiles are favorable, though inconsistencies remain. CONCLUSION: Valeriana species represent a promising multi-target strategy for insomnia, integrating neural and peripheral pathways. Future research should clarify the mechanisms underlying multi-organ effects, optimize formulations, and conduct rigorous clinical trials to establish standardized, effective, and safe interventions.
References
- 1.Yang, S., Zhang, H., Chen, L., Zhang, Z., Huang, L., Wang, W., Lu, W., Wang, Y., Wu, S., Hu, Z., Wang, S., Chen, R., & Liang, F. (2026). Valeriana species and insomnia: multi-organ mechanisms and translational perspectives. Pharmaceutical Biology. https://doi.org/10.1080/13880209.2026.2652660
Related Research
Sleep medicine
Concordance of wearable device sleep metrics with patient-reported sleep quality: A systematic review
3 Aug 2026
Sleep medicine reviews
Machine and deep learning in REM sleep behavior disorder: a scoping review and analysis of reporting quality
3 Aug 2026
Sleep medicine reviews
Artificial intelligence in sleep medicine I: Diagnosis, treatment, care, and research
2 Aug 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service